PRTK News and Press, Paratek Pharmaceuticals Inc. From 11/03/22

Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q3 GAAP EPS of -$0.38. Revenue of $30.2M (+23.5% Y/Y). For further details see: Paratek Pharmaceuticals GAAP EPS of -$0.38, revenue of $30.2M

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the Treatment of Pulmonary Anthrax -- Anno...

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners i...

BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022. The audio webcast...

Highlights include data from non-clinical and microbiology programs and real-world patient use BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization ...

BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...

Summary Today, we put Paratek Pharmaceuticals in the spotlight for the first time since the early fall of last year. Paratek is advancing its flagship product NUZYRA nicely, but shareholders have not been rewarded to this point in time even as the shares have strong analyst suppor...

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q2 2022 Earnings Call Aug 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q2 2022 Earnings Call Transcript